When was Kiora Pharmaceuticals founded?

Kiora Pharmaceuticals was founded in 2013 and raised its 1st funding round 10 years after it was founded.

Where is Kiora Pharmaceuticals located?

Kiora Pharmaceuticals is headquartered in Salt Lake City, United States. It is registered at Waltham, Massachusetts.

Who is the current CEO of Kiora Pharmaceuticals?

Brian M Strem of Kiora Pharmaceuticals.

How many employees does Kiora Pharmaceuticals have?

As of Jun 30, 2026, the latest employee count at Kiora Pharmaceuticals is 17.

Is Kiora Pharmaceuticals a funded company?

Kiora Pharmaceuticals is a funded company, having raised an undisclosed amount across 3 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Feb 17, 2023.

When was the latest funding round of Kiora Pharmaceuticals?

Kiora Pharmaceuticals' latest funding was a $***** Post IPO round on Apr 06, 2026, with participation from 0 investor.

What is the annual revenue of Kiora Pharmaceuticals?

Annual revenue of Kiora Pharmaceuticals is between $10M and $50M as on Dec 31, 2024

Where does Kiora Pharmaceuticals rank among its competitors?

Kiora Pharmaceuticals ranks 415th amongst 2868 active competitors, of which 985 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Kiora Pharmaceuticals?

Kiora Pharmaceuticals' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Kiora Pharmaceuticals - 2026 Company Profile, Team, Funding, Competitors & Financials

Kiora Pharmaceuticals is a public company based in Salt Lake City (United States), founded in 2013. It operates as a Developer of therapies for the treatment of different types of eye diseases. Kiora Pharmaceuticals has raised an undisclosed amount in funding. The company has 2868 active competitors, including 985 funded and 720 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Developer of therapies for the treatment of different types of eye diseases. The company lead product candidate KIO-301 is a molecular photoswitch that has the potential to restore light perception in patients with inherited and age-related retinal degeneration. Other drug candidates include KIO-101 for Dry Eye Disease, KIO-201 for PRK surgical recovery, and KIO-102 (Oral) for autoimmune diseases.

Website: kiorapharma.com
Social
Email ID: *****@kiorapharma.com
Phone Number: +1 **********
Registered Address: Waltham, Massachusetts

Key Metrics

Founded Year

2013

Location

Salt Lake City, United States

Stage

Public

Latest Funding Round

Post IPO, Apr 06, 2026, $*****

Investors

Nantahala Capital Management & 5 more

Ranked

415^th among 2868 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2024

Employee Count

17 as on Jun 30, 2026

Similar Companies

Sana Biotechnology & 622 more

Exit Details

Public

View Kiora Pharmaceuticals' full profile

Kiora Pharmaceuticals is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Kiora Pharmaceuticals, Inc. CIN: 980443284 , United States, Active	Dec 31, 1999	-	7 (As on Dec 31, 2022)	-
Eyegate Pharmaceuticals Inc CIN: 1372514 , United States, Active		$10M - $50M (As on Dec 31, 2024)	-	-
KIORA PHARMACEUTICALS, INC CIN: 98-0443284 , United States, Active	Dec 30, 2021	-	12 (As on Dec 31, 2022)	-

Kiora Pharmaceuticals got listed on Dec 14, 2017.

Click here to take a look at Kiora Pharmaceuticals's IPO in detail

Kiora Pharmaceuticals has raised funding over 3 rounds. Its first funding round was on Feb 17, 2023. Kiora Pharmaceuticals has 6 institutional investors.

Here is the list of recent funding rounds of Kiora Pharmaceuticals:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 06, 2026	7315057	Post IPO	9831685	4885634	2800089	3595245
Jan 31, 2024	7495890	Post IPO	4124928	7122727	1304914	Nantahala Capital Management & 4 more
Feb 17, 2023	2493437	Post IPO	3691390	3691942	2950561	2111652

Access funding benchmarks and valuations. Sign up today!

View details of Kiora Pharmaceuticals's funding rounds and investors

Kiora Pharmaceuticals' employee count trend

Kiora Pharmaceuticals has 17 employees as of Jun 26. Here is Kiora Pharmaceuticals's employee count trend over the years:

Employee count trend for Kiora Pharmaceuticals

Uncover Kiora Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Kiora Pharmaceuticals include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Kiora Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 18 others	73/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
10th	Celularity 2016, Warren (United States), Public	Developer of allogeneic cell therapies to treat multiple diseases	$290M	Celgene, Dreyfus Family Office & 8 others	71/100
415th	Kiora Pharmaceuticals 2013, Salt Lake City (United States), Public	Developer of therapies for the treatment of different types of eye diseases	-	Nantahala Capital Management, Rosalind Advisors ... & 4 others	53/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Kiora Pharmaceuticals's competitors? Click here to see the top ones

Kiora Pharmaceuticals has made no investments or acquisitions yet.

Here is the latest report on Kiora Pharmaceuticals's sector:

Free

Ophthalmology - Sector Report

Edition: July, 2026 (68 Pages)

View all reports related to Kiora Pharmaceuticals

Media has covered Kiora Pharmaceuticals for a total of 3 events in the last 1 year, 1 of them has been about company updates and 1 about partnerships.